Compare AbCellera Biologics Inc (ABCL) vs Broadcom Inc (AVGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Broadcom Inc — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Broadcom Inc trades at $392.9 (market cap $1.76T). The key difference: Broadcom Inc is far larger — about 748.9× AbCellera Biologics Inc's market cap, and Broadcom Inc pays a 0.7% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AVGO | |
|---|---|---|
Market Cap | $2.35B | $1.76T |
Sector | Health | Technology |
52-Week High | $8.12 | $481.57 |
52-Week Low | $2.78 | $271.80 |
Enterprise Value | $1.99B | $1.81T |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Broadcom (AVGO) trades at $370.78, up 2.87% today but remains in a bearish technical trend, 25% below its 52-week high. The company demonstrates strong fundamentals with Q1 2026 EPS beating estimates at $2.44 and robust revenue growth from $51.6B in 2024 to $63.9B in 2025. Recent news highlights a strategic partnership extension with Apple through 2031 for custom AI chips, providing long-term revenue visibility amid a challenging market environment for semiconductor stocks.
AVGO presents a compelling investment case with strong analyst support (88% buy ratings) and a $510.43 consensus price target representing 38% upside. However, elevated valuation multiples (P/E 62.21, P/S 24.17) and technical bearish signals warrant caution. The key opportunity lies in AVGO's AI semiconductor growth (143% YoY to $10.8B last quarter) while risks include market volatility and competitive pressures in the chip sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
